Hammersmith Medicines Research
London, United Kingdom
NCT Number: NCT02650076
The primary objective is to confirm the target receptor occupancy of SK-1405 and to correlate receptor occupancy with SK-1405 dose and plasma concentration.
The secondary objective is to assess the safety and tolerability of SK-1405 in healthy, Caucasian, male subjects.
Looking for future studies?
Notify Me20 year–50 year
Male
Interventional
Phase 1
London, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: up to 4 days
Sanwa Kagaku Kenkyusho Co., Ltd.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04950127
Bile Duct Diseases, Biliary Tract Diseases
Erlangen, Germany
View Trial DetailsNCT07641530
Hemodialysis, Pathological Conditions, Signs and Symptoms
Izmir, Turkey (Türkiye)
View Trial DetailsNCT06800755
Dry Skin, Pathological Conditions, Signs and Symptoms
Gdansk, Poland
View Trial DetailsNCT07478133
Pathological Conditions, Signs and Symptoms, Pruritus
Wuxi, Jiangsu, China
View Trial Details